MHC class II deficiency. Description of a clinical case
https://doi.org/10.21518/2079-701X-2015-16-78-82
Abstract
Currently, primary immunodeficiencies (PID) are becoming an increasingly relevant issue: it is now evident that this is not such a rare pathology as previously thought. According to the Immune Deficiency Foundation (USA), the total number of PID patients exceeds that of cystic fibrosis four-fold. Despite this, physician awareness of the disease is extremely low. The modern methods of diagnosis and treatment help the patients survive into adulthood. Patients with PID may get an appointment with any doctor: therapist, pulmonologist, hematologist, gastroenterologist, etc. since clinical manifestations of this disease are very diverse. Due to the fact that the prognosis for PID patients is determined by timeliness and adequacy of prescribed therapy, it is essential to study the various forms of PID to obtain new insights into the structure and principles of the human immune system.
About the Authors
T. V. Latysheva
State Research Center Institute of Immunology of the Federal Medical and Biological Agency, Moscow
Russian Federation
Russian Federation
E. A. Latysheva
State Research Center Institute of Immunology of the Federal Medical and Biological Agency, Moscow
Russian Federation
Russian Federation
I. A. Martynova
State Research Center Institute of Immunology of the Federal Medical and Biological Agency, Moscow
Russian Federation
Russian Federation
References
1. Hans D. Ochs, CI Edvard Smith, Jennifer M. Puck. Primary Immunodeficiency Deseases, amolecular and genetic approach. Oxford university press, 2013: 241-253.
2. Ouederni M, Vincent QB, Frange P et al. Major histocompatibility class II expression deficiency caused by RFXANK founder mutation: a survey of 35 patients. Blood, 2011. 10(19): 5108-18.
3. Al-Herz W, Alsmadi O, Melhem M, Recher M, Frugoni F, Notarangelo LD. Major histocompatibility complex class II deficiency in Kuwait: clinical manifestations, immunological findings and molecular profile. J ClinImmunol, 2013. 33: 513-9.
4. Suheir Hanna, MD, and Amos Etzioni, MD Haifa, Israel: MHC class I and II deficiencies. J Allergy ClinImmunol, 2014 Aug. 134(2): 269-75.
5. Nekrep N, Fontes J, Geyer M, Peterlin BM. When the lymphocyte loses its clothes. Immunity, 2003. 18: 453-7.
6. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol, 2001. 19: 331-73.
7. Хаитов Р.М. Аллергология и иммунология. М.: издательская группа «Гэотар-медиа», 2013: 209.
8. Abu-Arja RF, Gonzalez BE, Jacobs MR, Cabral L, Egler R, Auletta J, Arnold J, Cooke KR. Disseminated Bacillus Calmette-Guérin (BCG) infection following.
9. Saleem M, Arkwright P, Davies E, Cant A and Veys P. Clinical course of patients with major histocompatibility complex class II deficiency. Arch Dis Child, 2000 Oct. 83(4): 356-359.
10. Lev A, Simon AJ, Broides A, Levi J, Garty BZ, Rosenthal E, Amariglio N, Rechavi G, Somech R.: Thymic function in MHC class II-deficient patients. J Allergy ClinImmunol, 2013 Mar. 131(3): 831-9.
11. Al-Mousa H, Al-Shammari Z, Al-Ghonaium A, Al-Dhekri H, Al-Muhsen S, Al-Saud B, Arnaout R, Al-Seraihy A, Al-Jefri A, Al-Ahmari A, Ayas M, El-Solh H. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency. Biol Blood Marrow Transplant, 2010 Jun. 16(6): 818-23.
Review
For citations:
Latysheva TV, Latysheva EA, Martynova IA. MHC class II deficiency. Description of a clinical case. Meditsinskiy sovet = Medical Council. 2015;(16):78-82. (In Russ.) https://doi.org/10.21518/2079-701X-2015-16-78-82
Views:
660
Email this article 